Update of acute and long-term tolvaptan therapy

Teruhiko Imamura; Koichiro Kinugawa

doi:10.1016/j.jjcc.2018.10.003

Update of acute and long-term tolvaptan therapy

J Cardiol. 2019 Feb;73(2):102-107. doi: 10.1016/j.jjcc.2018.10.003. Epub 2018 Nov 9.

Authors

Teruhiko Imamura¹, Koichiro Kinugawa²

Affiliations

¹ Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.
² Second Department of Internal Medicine, Toyama University, Toyama, Japan. Electronic address: kinugawa-tky@umin.ac.jp.

PMID: 30420105
DOI: 10.1016/j.jjcc.2018.10.003

Abstract

One of the vasopressin type 2 receptor antagonists, tolvaptan, has been used to treat congestive heart failure patients for over seven years in Japan. Beyond the initially suggested standard procedure, tolvaptan is currently used in patients with acute heart failure soon after their admission or it is used for long-term treatment in the ambulatory situation. Nevertheless, definitive evidence is lacking, particularly for the implication of long-term tolvaptan therapy. Now is the time to update the accumulating evidence and consider the optimal therapeutic strategy for short- and long-term tolvaptan therapy.

Keywords: Aquaporin; Heart failure; Vasopressin.

Publication types

Review

MeSH terms

Acute Disease
Antidiuretic Hormone Receptor Antagonists / therapeutic use*
Chronic Disease
Heart Failure / drug therapy*
Humans
Japan
Time Factors
Tolvaptan / therapeutic use*

Substances

Antidiuretic Hormone Receptor Antagonists
Tolvaptan